HIF prolyl-hydroxylase inhibitors are members of a class of new drugs that act on the hypoxia-inducible factor (HIF) pathway. They are being investigated for treatment of anemia, chronic kidney disease[1], cancer[2], and for their effects on heart tissue[3] and others.[4]